# Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL

> **NCT04155710** · PHASE1 · COMPLETED · sponsor: **Iovance Biotherapeutics, Inc.** · enrollment: 7 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma

## Interventions

- **BIOLOGICAL:** IOV-2001
- **DRUG:** Low dose IL-2
- **DRUG:** High dose IL-2
- **DRUG:** IL-2

## Key facts

- **NCT ID:** NCT04155710
- **Lead sponsor:** Iovance Biotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-19
- **Primary completion:** 2024-11-11
- **Final completion:** 2024-12-02
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04155710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04155710, "Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04155710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*